Thyroid medication recall upgraded to FDA's highest risk level
September 24, 2026 3:52 PM EDT
The Brief
A thyroid medication that was recalled last month because it’s potentially "superpotent" has been upgraded to the Food and Drug Administration’s highest risk level.
The Thyroid, USP tablets were manufactured by Vitruvias Therapeutics and initially recalled on Aug. 24.
The FDA describes a Class I recall as "a situation in which there is a reasonable probability that the use of or exposure to a violative product will cause serious adverse health consequences or death."
https://www.livenowfox.com/news/thyroid-medication-recall-vitruvias-therapeutics-class-i